Exenatide, dapagliflozin or phentermine/topiramate differentially affect metabolic profiles in polycystic ovary syndrome
CONCLUSION: Dual therapy with EQW/DAPA was superior to either alone, DAPA/MET and PHEN/TPM in terms of clinical and metabolic benefits in this patient population.PMID:34097062 | DOI:10.1210/clinem/dgab408
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Karen E Elkind-Hirsch N Chappell Ericka Seidemann John Storment Drake Bellanger Source Type: research
More News: Adipex | Byetta | Dapagliflozin | DEXA Scan | Diabetes | Eating Disorders & Weight Management | Endocrinology | Eyes | Fortamet | Forxiga | Hormones | Insulin | Metformin | Obesity | Ovaries | Phentermine | Polycystic Ovary Syndrome | Sodium | Study | Topamax | Women